FDA sets August action date for Seattle’s oral HER2 drug tucatinibSeattle Genetics is a few months away from having its third drug product on the market, after the Share XFDA sets August action date for Seattle’s oral HER2 drug tucatinibhttps://pharmaphorum.com/news/fda-sets-august-action-date-for-seattles-oral-her2-drug-tucatinib/
Antibody-drug conjugates on the marchOne of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal Share XAntibody-drug conjugates on the marchhttps://pharmaphorum.com/views-analysis-oncology/antibody-drug-conjugates-on-the-march/
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in USPfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at Share XPfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in UShttps://pharmaphorum.com/news/pfizer-launches-biosimilars-to-roches-big-three-cancer-drugs-in-us/
Google Health’s AI outperforms radiologists at breast cancer screeningAn artificial intelligence (AI) system from Google Health can identify breast cancer more accurately than radiologists, according to Share XGoogle Health’s AI outperforms radiologists at breast cancer screeninghttps://pharmaphorum.com/news/google-heaths-ai-outperforms-radiologists-at-breast-cancer-screening/
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filingThe FDA has approved an advanced breast cancer drug from AstraZeneca and Daiichi Sankyo in super-quick time. The Share XFDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filinghttps://pharmaphorum.com/news/fda-hastily-approves-daiichi-sankyo-azs-cancer-drug/
AZ sells ex-US rights to old cancer drugs Arimidex and CasodexFor several years AstraZeneca has been selling off rights to its older drugs to raise cash as it Share XAZ sells ex-US rights to old cancer drugs Arimidex and Casodexhttps://pharmaphorum.com/news/az-sells-ex-us-rights-to-old-cancer-drugs-arimidex-and-casodex/
AZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseaseAstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi Share XAZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseasehttps://pharmaphorum.com/news/az-daiichi-sankyos-breast-cancer-drug-delays-progression-in-advanced-disease/
Mylan and Biocon launch Herceptin biosimilar in USMylan and Biocon have launched their Herceptin biosimilar Ogivri in the US, the second challenger to Roche’s breast Share XMylan and Biocon launch Herceptin biosimilar in UShttps://pharmaphorum.com/news/mylan-and-biocon-launch-herceptin-biosimilar-in-us/
NICE backs Ibrance for breast cancer via Cancer Drugs FundPfizer’s Ibrance has been approved for use by the NHS in England as a second-line treatment for advanced Share XNICE backs Ibrance for breast cancer via Cancer Drugs Fundhttps://pharmaphorum.com/news/nice-backs-ibrance-for-breast-cancer-via-cancer-drugs-fund/
